Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalised Disease Monitoring During Treatment With an Aromatase Inhibitor + Cyclin Dependent Kinase (CDK) 4/6 Inhibitor as 1st Line Endocrine Therapy in Patients With ER-positive/HER2-negative Metastatic Breast Cancer

NCT04597580 is registered in ClinicalTrials.gov with The Christie NHS Foundation Trust as lead sponsor.

NCT NCT04597580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04597580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalised Disease Monitoring During Treatment With an Aromatase Inhibitor + Cyclin Dependent Kinase (CDK) 4/6 Inhibitor as 1st Line Endocrine Therapy in Patients With ER-positive/HER2-negative Metastatic Breast Cancer
Lead sponsor
The Christie NHS Foundation Trust
Phase
Observational
Overall status
Active, not recruiting
Start date
May 8, 2019
Completion date
January 31, 2030
Enrollment
97 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic, estrogen receptor-positive breast cancer